Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 10/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1926955 | 0.90 | MGLL (0.39) | MGLLCHRM3CHRM2CHRM1HDAC1 | |
| SCHEMBL1929739 | 0.89 | CHRM2 (0.38) | MGLLCHRM3CHRM2CHRM1HDAC1 | |
| SCHEMBL1926764 | 0.87 | HRH4 (0.37) | MGLLHDAC1HDAC2HDAC3HRH4 | |
| SCHEMBL1929689 | 0.87 | MGLL (0.43) | MGLLCHRM3CHRM2CHRM1HRH4 | |
| SCHEMBL1927258 | 0.86 | HRH4 (0.39) | MGLLCHRM3CHRM2CHRM1HDAC1 | |
| SCHEMBL1927773 | 0.84 | HRH4 (0.40) | MGLLHDAC1HDAC2HDAC3HRH4 | |
| SCHEMBL1929713 | 0.84 | HRH4 (0.38) | MGLLHRH4HRH3 | |
| SCHEMBL1927703 | 0.83 | HRH4 (0.37) | MGLLHDAC1HDAC2HDAC3HRH4 | |
| SCHEMBL1926152 | 0.79 | ACHE (0.41) | — | |
| SCHEMBL1927361 | 0.78 | ACHE (0.40) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101559053-A | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-10-21 | — | — | CN | claimed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | claimed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | claimed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | claimed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | claimed |
| US-8288560-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | IPSEN PHARMA S.A.S. (FR) | 2011-07-14 | — | — | US | disclosed |
| US-7956075-B2 | Thiazole, oxazole, imidazole, isoxazole and isoxazoline derivatives, e.g., butyl 2-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate inhibit lipidic peroxidation and monoamine oxidase and modulate sodium channels and are used for treating neurodegenerative disorders or pain. | IPSEN PHARMA S.A.S. (FR) | 2011-06-07 | — | — | US | disclosed |
| CN-101559053-A | 5-membered heterocycle derivatives, production thereof and use thereof as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-10-21 | — | — | CN | disclosed |
| CN-100488506-C | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2009-05-20 | — | — | CN | disclosed |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | LASSAUNIERE PIERRE-ETIENNE CHA | 2008-06-19 | — | — | US | disclosed |
| US-7291641-B2 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2007-11-06 | — | — | US | disclosed |
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2007-08-02 | — | — | US | disclosed |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-02-17 | — | — | US | disclosed |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-07-08 | — | — | US | disclosed |
| CN-1391474-A | 5-membered heterocyclic derivatives, their preparation and their use as medicaments | SOD CONSEILS RECH APPLIC (FR) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179153-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | PARK7, SNCA, SDHA | MGLL 3259/4885CHRM3 1002/4885CHRM2 1469/4885 |
| US-20050038087-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, OPRK1 | MGLL 3702/4885CHRM3 403/4885CHRM2 590/4885 |
| US-20040132788-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OPRK1, HCN1, P2RX7 | MGLL 3588/4885CHRM3 969/4885CHRM2 1230/4885 |
| US-20110172434-A1 | DERIVATIVES OF HETEROCYCLES WITH 5 MEMBERS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | OXER1, OPRL1, CHRNA7 | MGLL 3104/4885CHRM3 373/4885CHRM2 604/4885 |
| US-20080146627-A1 | Derivatives of heterocycles with 5 members, their preparation and their use as medicaments | OXER1, OPRL1, P2RX7 | MGLL 4059/4885CHRM3 339/4885CHRM2 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.